A Phase 2 interventional study of 18F-PSS232 in Healthy, sponsored by University of Zurich. Terminated at 1 site in Switzerland. Open to participants aged 20 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-08-12.
Sponsored by University of Zurich · Phase 2, Interventional, and Diagnostic
Based on PET (18-PSS232) and MRI, glutamate release after N-acetylcystein challenge will be monitored in human brains.
Diagnostic trial with quantification of glutamate release in PET/MR.
University of Zurich is the lead sponsor of 1,030 studies on the registry; 130 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Subjects receive baseline PET with 18F-PSS232 and stimulation PET with 18F-PSS232 after medical challenge with N-acetylcystein
Drug: 18F-PSS232
Diagnostic PET Tracer
Also known as: 18FABP
Difference of Binding Potentials of 18F-PSS232 in different brain regions between Baseline PET and PET after medical challenge
for details, please see Innis: Journal of Cerebral Blood Flow \& Metabolism (2007) 27, 1533-1539
Time frame: Baseline PET and PET after medical challenge will be scanned within 3 months
This study is terminated, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Zurich